Bourgeon Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Bourgeon Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,344	Closed	-$74K	–	100
2017 Q3	$74K	Buy	+1,344	New	+$227K	0.04%	84
2017 Q2	–	Sell	-2,025	Closed	-$242K	–	96
2017 Q1	$242K	Sell	2,025 -625	-24%	-$65.5K	0.15%	72
2016 Q4	$263K	Sell	2,650 -188	-7%	-$19.8K	0.17%	74
2016 Q3	$318K	Sell	2,838 -62	-2%	-$7.44K	0.2%	67
2016 Q2	$298K	Buy	2,900 +312	+12%	+$31.2K	0.19%	67
2016 Q1	$238K	Buy	2,588 +1,338	+107%	+$143K	0.16%	77
2015 Q4	$180K	Sell	1,250 -1,250	-50%	-$163K	0.12%	86
2015 Q3	$258K	Buy	+2,500	New	+$293K	0.18%	80

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IPLA

Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bourgeon Capital Management's SIOX Position: Q4 2017 in Review

Bourgeon Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 1,344 shares — an estimated $74K sold.

Bourgeon Capital Management first reported a position in SIOX in Q3 2015 and held it in 8 quarters. The position peaked at $318K in Q3 2016. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

Bourgeon Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Bourgeon Capital Management sold 1,344 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $74K.
Bourgeon Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 8 quarters.
Bourgeon Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $318K in Q3 2016.
104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Bourgeon Capital Management's 13F filing for Q4 2017, filed 5 Feb 2018.